Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 5/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10883348 | 1.00 | PPARA (0.54) | PPARACTSSPPARGSYKCTSK | |
| SCHEMBL11291089 | 0.91 | REN (0.54) | PPARACTSSSYKCTSKSMN1; SMN2 | |
| SCHEMBL7290254 | 0.91 | CTSK (0.54) | PPARACTSSSYKCTSKCTSL | |
| SCHEMBL957159 | 0.90 | PPARA (0.56) | PPARACTSSPPARGSYKCTSK | |
| SCHEMBL2707177 | 0.90 | PPARA (0.56) | PPARACTSSPPARGSYKCTSK | |
| SCHEMBL203720 | 0.90 | PPARA (0.56) | PPARACTSSPPARGSYKCTSK | |
| SCHEMBL10054776 | 0.90 | PPARA (0.56) | PPARACTSSPPARGSYKCTSK | |
| SCHEMBL27578688 | 0.90 | PPARA (0.56) | PPARACTSSPPARGSYKCTSK | |
| SCHEMBL1517760 | 0.89 | PPARA (0.55) | PPARACTSSPPARGSYKCTSK | |
| SCHEMBL3817109 | 0.89 | PPARA (0.55) | PPARACTSSPPARGSYKCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0815833-B1 | Malodour preventing agents | GIVAUDAN SA (CH) | 2003-04-09 | — | — | EP | claimed |
| US-5925339-A | ODORLESS DEODORANTS AND ANTIPERSPIRANTS | GIVAUDAN ROURE SA (CH) | 1999-07-20 | — | — | US | claimed |
| EP-0815833-A2 | Malodour preventing agents | GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) | 1998-01-07 | — | — | EP | claimed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| WO-2020198435-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2013100132-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | 中外製薬株式会社 (JP) | 2013-07-04 | — | — | WO | disclosed |
| US-7807678-B2 | Peptidomimetics of biologically active metallopeptides | PALATIN TECHNOLOGIES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20090253713-A1 | Small Molecule Compositions for Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-7550602-B1 | Small molecule compositions for sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7326707-B2 | Bicyclic melanocortin-specific compounds | PALATIN TECHNOLOGIES INCORPORATED (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1425029-A4 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | PALATIN TECHNOLOGIES INC (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2003013571-A1 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| US-6362165-B1 | Hydroxyphenyl derivatives with HIV integrase inhibitory properties | PHARMACOR INC. (CA) | 2002-03-26 | — | — | US | disclosed |
| EP-1165492-A1 | HYDROXYPHENYL DERIVATIVES WITH HIV INTEGRASE INHIBITORY PROPERTIES | Pharmacor Inc. (CA) | 2002-01-02 | — | — | EP | disclosed |
| US-6150542-A | COSMETICS; IN DEODORIZERS, ANTIPERSPIRANTS | GIVAUDAN ROURE (INTERNATIONAL) SA (CH) | 2000-11-21 | — | — | US | disclosed |
| WO-2000059867-A1 | HYDROXYPHENYL DERIVATIVES WITH HIV INTEGRASE INHIBITORY PROPERTIES | PHARMACOR INC. (CA) | 2000-10-12 | — | — | WO | disclosed |
| EP-0691422-B1 | Process for the preparation of substituted diaminodicarboxylic acid derivatives | NYCOMED AUSTRIA GMBH (AT) | 1999-11-03 | — | — | EP | disclosed |
| US-5925339-A | ODORLESS DEODORANTS AND ANTIPERSPIRANTS | GIVAUDAN ROURE SA (CH) | 1999-07-20 | — | — | US | disclosed |
| EP-0815833-A2 | Malodour preventing agents | GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) | 1998-01-07 | — | — | EP | disclosed |
| EP-0691422-A1 | Process for the preparation of substituted diaminodicarboxylic acid derivatives | Hafslund Nycomed Pharma AG (AT) | 1996-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253713-A1 | Small Molecule Compositions for Sexual Dysfunction | PDE3B, PDE3A, PDE5A | PPARA 4448/4885CTSS 2907/4885PPARG 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.